StockMirror — Stock Screener

ANTHEM Q1 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Anthem Biosciences reported a soft Q1 FY27 with consolidated revenues of Rs. 418 Cr (CRDMO Rs. 341 Cr, Specialty Rs. 78 Cr), impacted by customer delivery deferrals. EBITDA margin remained strong at 39.6%, PAT margin at 27.1%. Management maintains full-year growth and margin outlook, citing 60% order book visibility, new customer additions, and capacity ramp-up (Unit 3 at 30-35% utilization and Unit 4 construction). Key positives include improving material margins via yield optimization and declining ESOP costs. Key risks include lumpy revenue and regulatory delays for Semaglutide API.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized sustainable double-digit growth (via order book, capacity expansion, new customers) while maintaining industry-leading EBITDA/PAT margins through cost efficiencies, technology, and yield improvements. They explicitly said margins will remain intact despite revenue lumpiness.

About Anthem Biosciences Limited

Anthem Biosciences Limited (ANTHEM) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More